We rank companies based on fund manager, research analyst and news sentiment
ATOS stock icon

Atossa Therapeutics, Inc. Common Stock
ATOS

$1.66
6.21%
 

About: Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Employees: 10

0
Funds holding %
of 6,474 funds
Analysts bullish %
0
News positive %
of 10 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

298% more call options, than puts

Call options by funds: $144K | Put options by funds: $36.1K

18% more capital invested

Capital invested by funds: $11.9M [Q3] → $14.1M (+$2.19M) [Q4]

0.11% less ownership

Funds ownership: 12.85% [Q3] → 12.74% (-0.11%) [Q4]

10% less funds holding

Funds holding: 52 [Q3] → 47 (-5) [Q4]

61% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 18

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$4
141%
upside
Avg. target
$4
141%
upside
High target
$4
141%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Emily Bodnar
141%upside
$4
Buy
Maintained
2 Apr 2024
HC Wainwright & Co.
Emily Bodnar
141%upside
$4
Buy
Initiated
12 Feb 2024

Financial journalist opinion

Based on 10 articles about ATOS published over the past 30 days